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Abstract
Background: Parkinsonism is a complex multifactorial neurodegenerative disorder, in which genetic and environmental
risk factors may both play a role. Among environmental risk factors cocaine was earlier ambiguously linked to
Parkinsonism. Former single case reports described Parkinsonism in chronic cocaine users, but an epidemiological study
did not confirm an increased risk of Parkinson’s disease. Here we report a patient, who developed Parkinsonism in young
age after chronic cocaine use, in whom a homozygous LRRK2 risk variant was also detected.
Case presentation: The patient was investigated because of hand tremor, which started after a 1.5-year period
of cocaine abuse. Neurological examination suggested Parkinsonism, and asymmetrical pathology was confirmed by
the dopamine transporter imaging study. The genetic investigations revealed a homozygous risk allele in the LRRK2
gene. After a period of cocaine abstinence, the patient’s symptoms spontaneously regressed, and the dopamine
transporter imaging also returned to near-normal.
Conclusions: This case report suggests that cocaine abuse indeed might be linked to secondary Parkinsonism
and serves as an example of a potential gene-environmental interaction between the detected LRRK2 risk variant
and cocaine abuse. The reversible nature of the DaTscan pathology is a unique feature of this case, and needs
further evaluation, whether this is incidental or can be a feature of cocaine related Parkinsonism.
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Background
Pathomechanism of Parkinson’s disease (PD), which is
the second most common neurodegenerative disorder, is
defined by the progressive loss of dopaminergic neurons
in the substantia nigra [1]. The dopaminergic system
plays an important role in several vital mechanisms, such
as movement control, cognition and controlling reward.
For the normal functioning of dopaminergic neurons the
dopamine reuptake is essential from the synaptic cleft
into presynaptic neurons via dopamine transporters [2].
There are several drugs (such as cocaine) causing
increased extracellular level of dopamine resulting in
euphoric effects and motoric symptoms [3].
In case of PD, there are evidences, which suggest that
dopamine transporter (DAT) dysregulation is also a
factor in the disease mechanism [4]. Cocaine enhances
dopaminergic signalling as it binds to DAT and blocks
the reuptake of dopamine from the synaptic cleft [5].
The suspected association between cocaine abuse and
the increasing risk of PD was previously described in
several patients [6] although there are several cases
where despite cocaine abuse no correlation with PD was
observed [7].
Although the evidences for higher risk of PD among
cocaine users is controversial, it is already proved that
the brain structure is altered and the conformation of
alpha-synuclein become more compact [8]. In PD patho-
genesis the misfolded alpha-synuclein plays crucial role
in the death of dopaminergic neurons therefore in the
progression of PD [9]. In cocaine abusers overexpression
of alpha-synuclein has been described in dopaminergic
neurons, potentially increasing the risk for degenerative
changes in dopaminergic neurons [10]. As SNCA is one
of the most common cause of PD there are possibility
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that other genetic risk factors, such as PARK2, LRRK2,
PINK1 and DJ-1 [11], also could contribute to the devel-
opment of PD even in early age due to the cumulated
effect of cocaine abuse and genetic risk.
DAT-SPECT (dopamine transporter single photon emis-
sion computed tomography) imaging enables differenti-
ation of neurodegenerative causes of Parkinsonism, from
other movement or tremor disorders where typically the
DAT-SPECT study will be normal. Impaired function of
DAT is reducing striatal binding of DaTSCAN, however it
is not specific to PD. Several cocaine analogues labelled
with 123I sufficient for SPECT binds with high affinity to
DAT [12]. The most common analogue in the clinical
practice is 123I-FP-CIT (DaTSCAN, GE Healthcare) [12].
The method can measure either the DAT density on the
presynaptic terminal, or nigrostrital fiber density.
In our case study we are discussing the association of
the genetic and environmental factors in a cocaine user
young patient with reversible Parkinsonian symptoms.
Case presentation
A 44 years old male patient was referred to our neuroge-
netic outpatient clinic, for examination of hand tremor. In
the past medical history gastroesophageal reflux disease
(Los Angeles grade A), LIV-V discus herniation and Type
I (Wenckebach) second-degree atrioventricular block was
present. The latter caused no symptoms, and no medical
intervention was necessary. The patient took pantoprazol
regularly. Before the onset of the hand tremor the patient
used nasal cocaine regularly for a period of 18month. He
used ~ 1 g/day (15mg/kg) with nasal insufflation. During
the cocaine use irritability and insomnia, dissociative
symptoms such as depersonalization and derealisation, de-
veloped. Because of the latter he stopped cocaine use 10
months before the examination. He realized his hand
tremor approximately 3–4months after cessation of the
drug.
During the neurological examination hand tremor af-
fected asymmetrically the right hand more than the left
hand, and was mainly postural increasing with holding
small weights. In addition, signs of mild Parkinsonism
(mild bradykinesia and rigor in the right hand) was also
detected. Altogether, the neurological examination
suggested incipient Parkinsonism, but the tremor was
atypical (not resting type). According to the MDS classi-
fication of tremors [13] it was classified as isometric
tremor syndrome. From the family history, it is notice-
able that the father of the patient suffered from postural
hand tremor in older age. The son of our patient was
examined because of restless leg syndrome at age 13
years. Routine blood studies were normal, including cop-
per, ferritin and ceruloplasmin. Abdominal ultrasound
was normal. Brain MRI (3 T) showed no structural or
vascular lesions, basal ganglia were normal, but absence
of swallow tail sign was detected (Fig. 1), suggesting
Parkinson’s disease. For further clarification DaTscan
was performed by a double-headed SPECT system (GE
Infinia II with Xeleris workstation) using a standard ac-
quisition protocol according to the EANM guideline
[12] with 170MBq I-123-Ioflupane tracer. This tracer
has a high affinity not only to DAT but to the serotonin
transporter (SERT) and norepinephrine transporter
(NET) as well [14]. However, the concentration of DAT
in the basal ganglia is much higher, than that of the
other transporters, therefore its measure is appropriate
for DAT. The striatal binding was evaluated both by
semiquantitative visual evaluation and for a more accur-
ate comparison the DaTQUANT software (created by
GE Healthcare in 2013 adapted in 2015, as a quantitative
binding method with normal database) has been used
[15]. It showed asymmetrically decreased radiopharma-
con binding on the right side in the caudate nucleus 3.0
h after intravenous injection of the I-123-Ioflupane
(Fig. 2/a). During the time of the DaTscan no cocaine
use has been reported. Although we had only self-report
about the cocaine use, the long-term observation of the
patient and the close follow-up with a good compliance,
and the improvement of the clinical symptoms con-
vinced us about the reliability of the anamnestic data.
For the genetic investigation DNA was isolated from
blood with QIAamp DNA blood kit, according to the
manufacturer’s protocol (QIAgen, Hilden, Germany).
Sanger sequencing was performed in the whole coding
region and exon/intron boundaries of SNCA, PARK2
and PINK1, LRRK2 gene by using ABI Prism 3500 DNA
Sequencer (Applied Biosystems, Foster City, USA).
Exonic copy number variations were analyzed by multi-
plex ligation-dependent probe amplification (MLPA,
SALSA MLPA Kit P051-D1 Parkinson; MRC Holland,
Amsterdam, The Netherlands). In the LRRK2 gene a
homozygous risk factor variant, NM_198578.4:c.4939
T > A, p.Ser1647Thr (codon change: TCA > ACA) was
detected [16]. The segregation analysis detected the
S1647 T LRRK2 variant in heterozygous state in the
parents of the patient. MLPA did not detect any exonic
copy number variations. Based on the clinical and
DaTscan findings we suspected Parkinson syndrome,
associated with a toxic-genetic interaction. Selegiline
was prescribed, but the patient omitted the medica-
tion, because the tremor was worsening from the
drug. After 1 year of cocaine abstinence the tremor
significantly decreased. One and half year after the
first DaTscan a control investigation was performed,
and showed normal radiopharmacon binding in the
striatum, with only mild asymmetry. The right caud-
ate binding returned into the normal range, and the
right striatal binding was higher than at the first
examination (Fig. 2/b).
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Discussion and conclusions
Cocaine use is associated with a range of movement
disorders [3], and has complex effects on the central
nervous system. Possible ways to categorize these effects
is based on time characteristics, i.e. neurologic complica-
tions with acute or chronic use, or whether the patient is
an active user, early or late abstinent. The main acute
pharmacological effect of cocaine is dopamine (DA)
reuptake inhibition, which elevates synaptic DA levels.
Literature information about cocaine’s effect on dopa-
mine transporter (DAT) level expression in human is
scarce and available information from experimental
animal studies are also contradictory at times. There are
two possible mechanism supported by the literature, by
which we tried to interpret our findings, i.e. the low
DAT binding, which later normalized.
On one hand, in response to the elevated DA levels,
DAT downregulation might take place, as a compensatory
mechanism [17]. This compensatory mechanism decreases
the acute DA elevation with the use of cocaine, but on the
long term it leads to DA deficiency in the caudate nucleus
and frontal cortex as DA synthesis and reuptake is both
needed for synaptic storage [18]. In acute cocaine abstin-
ence the DATs start to upregulate as shown by other
DaTscan studies [19]. This might explain our results, why
we have seen decreased DAT binding, which later normal-
ized. In this scenario we hypothesize that DaTscan in our
patient was performed in a time window when DAT levels
are still decreased; however, the patient was already abstin-
ent. As an acute withdrawal symptom decreasing DA level
results in psychological symptoms, restlessness and tremor
[20]. Long term use of cocaine however also results in
DAT decrease, and this might explain Parkinsonian fea-
tures in abstinence as a result of DA depletion.
On the other hand, other studies in the literature
suggest, that cocaine increases DAT expression, and
abstinence of cocaine intake for a prolonged period of
time decreases DAT level [5]. In this scenario, we can
hypothesize that we have seen the decreased DAT-
binding, because the patient was already abstinent for a
long time, and this change in the expression later
normalized.
It should be mentioned that the above described
mechanisms are speculative and the effects of cocaine
on the nervous system is complex. We also need to
consider changes in D2 receptor expression [21] and
possible long-term structural damage to dopaminergic
synaptic terminals [18]. Effects might be dose and for-
mulation dependent, as neurologic complications are
more common with the smokable alkaloidal form of
cocaine, known as „crack” [22]. Acute blood pressure
elevations and cerebral vasospasm might also cause
cerebrovascular events, such as acute ischemic stroke, or
aneurysm rupture [23], but small subclinical ischemic
events may also cause structural damage in the brain.
Chronic cocaine abuse lead to increased age-dependent
temporal lobe cortical atrophy [24], and decreased
frontal white matter connectivity [25] shown by imaging
studies.
The association of cocaine use with Parkinsonism is
nevertheless complicated, and the literature information is
scarce. On one hand, the acute elevation of synaptic DA
levels may ameliorate “off” periods in Parkinson’s disease
patients [26]. On the other hand chronic use was associ-
ated with Parkinsonian features in many case reports [20],
although this was not confirmed by the epidemiological
study of Callaghan et al. [27]. The above described mech-
anism suggests a pharmacological, reversible form of
Fig. 1 Brain MRI of the patient. On the axial susceptibility weighted images in the plane of the mesencephalon, the substantia nigra is
identifiable both sides. The swallow tail sign is normally present in 3 T imaging at the area indicated by the arrows, but it is absent in the patient
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secondary Parkinsonism in our case. However, a further
possible, non-pharmacologic link between Parkinsonism
and chronic cocaine use might exist. Chronic cocaine ex-
posure triggers alpha-synuclein overexpression [10], which
might be an acute protective mechanism against increased
oxidative stress, but which eventually lead to formation of
Lewy bodies (LBs), and accelerated neurodegeneration.
Besides, cocaine also physically binds to alpha-synuclein,
which might cause deleterious conformational changes
[8]. However, it is not probable, that these changes will
cause reversible pathology on the DaTscan.
The long-term cocaine use has not the same effect as
dopamine receptor blocking agents - DRBA, however these
can induce also parkinsonism. Drug-induced Parkinsonism
(DIP) should resolve after the causative agent has been
withdrawn. Lim et al. [28] reported that Parkinsonism
might persist for more than 6months after discontinuation
of the DRBA, and DaTscan showed normal striatal
dopamine transporter binding at that time. Nine months
after the discontinuation of the dopamine receptor block-
ing agent, Parkinsonism was significantly improved in their
patients but not completely resolved [28].
In a number of patients, with DIP symptoms persist or
may even worsen over time, suggesting the development of
concomitant PD. There are speculations that the possible
neurotoxic effect of neuroleptics exerted on a susceptible
dopaminergic system would lead to a progressive process.
To which extent a personal susceptibility plays a role
remains to be determined and further genomic studies in
patients exposed to neuroleptics who develop DIP or PD
could eventually identify a genetic background of suscepti-
bility [29]. Even if the pathomechanism is not the same in
the cocaine induced Parkinsonism and DIP the personal
susceptibility can be an important factor.
In our case the PD associated genes were investigated
since the patient has movement disorders in his family.
Fig. 2 DaTscan of the patient in two time points. The Figure shows the radiopharmacon binding in the area of the basal ganglions. The
measurements and calculated ratios for quantitative analysis in the volumes of interest are also listed. Figure a was taken after the first
examination of the patient. At this time decreased radiopharmacon binding was present in the right striatum (mainly the caudate). Figure b was
taken after 1 year of cocaine abstinence. At this time point, normal binding is detectable in the right caudate
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We detected only one genetic risk variant, which was
previously associated with PD. The presence of this
homozygous LRRK2 polymorphism (S1647 T) has a very
mild association with PD, with a low odds ratio (in our
cohort OR: 1.787, 95%, CI: 0.8052 to 3.96 – Illes et al.,
unpublished data). In the presence of this genetic risk
variant, even in homozygous status, appearance of
Parkinsonism is not likely, but hypothetically in the
presence of some environmental factors, which may
influence dopamine level it may present itself. Similar
mechanism was suggested by Lin et al. [30] in a Taiwanese
population, where the S1647 T variant was only associated
to Parkinsonism when environmental exposures were in-
cluded in the logistic regression model. Further published
studies indicated also significant interactive effects be-
tween environmental factors and genetic variants [31].
These kind of interactions are well described in the case
of the serotonin transporter polymorphism association
with depression [32]. However, it should be kept in mind
that proof of the additional effect of LRRK2 S1647 T poly-
morphism and cocaine abuse goes beyond the framework
of our case study.
It is interesting, that in our patient, the MRI already
showed some structural changes (absence of the swallow
tail sign), indicating the damage of nigrostriatal pathway,
and thus the acute pharmacological effect of cocaine
might be also altered. The family history of hand tremor
in the father and restless-leg syndrome in the child also
suggest some already existing non-pharmacologic risk at
the patient.
In summary, this case report may raise the possibility
of a gene-environment interactions in the background of
our patient’s symptoms. Our result suggests that some
of these effects in the early state might partially revers-
ible, as after a period of abstinence the patient’s Parkin-
sonian symptoms resolved. However, the patient needs
longitudinal follow-up, as PD might later reoccur, as
the consequence of the chronic effects of cocaine,
and the additive effects of the LRRK2 alteration. Fur-
ther studies of S1647 T alteration and environmental
interaction in a larger Hungarian cohort and func-
tional studies in in vivo models are warranted to val-
idate our hypothesis.
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